Pegloticase

Drug #2267

Peglotigase which is a PEGylated uric acid specific enzyme obtained from genitically modified mammalin urate oxidase(uricase) which achieves it therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Pegylated Uric acid Enzyme.

It belongs to Uric Acid Lowering Agent pharmacological group on the basis of mechanism of action.

Molecular Weight: 540 · Non-proprietary name: Pegloticase.

Pharmacokinetics

None recorded.

Indications

Pegloticase is primarily indicated in conditions like Asymptomatic Hyperuricemia, Gout.

Contraindications

Pegloticase is contraindicated in conditions like G6pd deficiency.

Dosage

Pegloticase's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
8 mg	8 mg	—	IV	Pegloticase should be administered Every 2 weeks. Dilute solution Pegloticase to reach Room Temperature. Donot institute Pegloticase therapy with oral urate lowering agents. donot Administer as IV push or Bolus Administer IV infusion over no less than 120minutes via gravity feed, syringe type pump or infusion pump Monitor serum Uric Acid Level
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Pegloticase in overdosage may give rise to further complications which include Congestive heart failure .

Pegloticase produces potentially life-threatening effects which include Anaphylaxis . Careful monitoring is needed with proper medical management.

Pegloticase is known to cause more or less tolerable side effects which are usually transient. These include Chest pain, Constipation , contusion, Dyspnea, Ecchymoses, Erythema, gout flares, Infusion reactions, 1st dose, Nasopharyngitis, Nausea and vomiting, Pruritus , Urticaria.

Warnings / Precautions

pegloticase should be administered by a healthcare provider. patient should be pre medicated with Antihistamines and Cortico steroids. Patient should be closely monitored for Anaphylaxis. Monitor Serum Uric Acid level prior to infusion , Discontinue treatment if level increase to above 6mg/dl. monitor closely for sign and symptoms of infusion reaction. Excercise caution in patient who have Congestive heart failure.

Available Brands

None recorded.

Storage Conditions

Pegloticase should be stored .

Drug Classification

1.2.3 — Antigout preparations